Alexion Pharmaceuticals Inc (ALXN)

135.54
1.40 1.00
NASDAQ : Health Care
Prev Close 136.93
Open 136.19
Day Low/High 134.57 / 136.80
52 Wk Low/High 110.56 / 205.29
Volume 356.28K
Avg Volume 3.21M
Exchange NASDAQ
Shares Outstanding 223.93M
Market Cap 30.66B
EPS 0.70
P/E Ratio 82.99
Div & Yield N.A. (N.A)

Latest News

Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now

Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now

This drug maker has risen more than 17% this year. But investors may want to say cautious, unless they are super-aggressive.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris® (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris® (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company has submitted marketing applications to the U.

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.

Alexion To Present At The 35th Annual J.P. Morgan Healthcare Conference

Alexion To Present At The 35th Annual J.P. Morgan Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 35th Annual J.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016

Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced today that it has filed with the Securities and Exchange Commission its Form 10-Q for the third quarter ended September 30, 2016.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Here's Your Last Chance to Sell Shake Shack, 4 More 'Toxic Stocks' in 2016

Here's Your Last Chance to Sell Shake Shack, 4 More 'Toxic Stocks' in 2016

The S&P 500 may be ending 2016 with double-digit gains, but almost a third of the index's individual stocks are actually down this year. Here's how to avoid the laggards.

Dump These 5 'Toxic Stocks' Before the New Year

Dump These 5 'Toxic Stocks' Before the New Year

Start 2017 on the right foot by selling your holdings in these five stocks.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Alexion Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Alexion Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Alexion Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Class Action Lawsuit Against Alexion Announced By Holzer & Holzer

SHAREHOLDER ALERT: Class Action Lawsuit Against Alexion Announced By Holzer & Holzer

Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors in Alexion Pharmaceuticals, Inc.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Alexion Announces Phase Two Trial Failure, Falls Slightly After Hours

Alexion Announces Phase Two Trial Failure, Falls Slightly After Hours

The biotech company has been taking a beating lately.

Alexion Announces Top-Line Results From Phase 2/3 PROTECT Study Of Eculizumab (Soliris®) For The Prevention Of Delayed Graft Function (DGF) After Kidney Transplantation

Alexion Announces Top-Line Results From Phase 2/3 PROTECT Study Of Eculizumab (Soliris®) For The Prevention Of Delayed Graft Function (DGF) After Kidney Transplantation

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today reported results from the PROTECT Study, a Phase 2/3 registration trial of eculizumab (Soliris ®) for the prevention of delayed graft function (DGF) after kidney...

ALXN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Alexion Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

ALXN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Alexion Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alexion Pharmaceuticals, Inc.

Biogen Looks Within for Next CEO, Raising Concerns Top Outside Talent Passed on Job

Biogen Looks Within for Next CEO, Raising Concerns Top Outside Talent Passed on Job

Biogen promoted its current Chief Commercial Officer Michel Vounatsos to become the biotech company's next CEO.

ALXN LOSS ALERT: Rosen Law Firm Reminds Alexion Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - ALXN

ALXN LOSS ALERT: Rosen Law Firm Reminds Alexion Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - ALXN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Alexion Pharmaceuticals, Inc.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

Alexion Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Alexion Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...